Choosing the First Antihypertensive by Comorbidity: Diabetes, CKD, Heart Failure, Pregnancy and Age

The first antihypertensive is chosen by comorbidity, not by habit. With no compelling indication, a thiazide-type diuretic, a long-acting dihydropyridine calcium channel blocker, or an ACE inhibitor or ARB is equally correct. When the vignette adds CKD, diabetes with albuminuria, heart failure, coronary disease, pregnancy or advanced age, one class moves ahead of the others, and some classes become wrong answers.

The decision to treat (stage, PREVENT risk, goal) is covered in the hypertension staging article; this one assumes treatment is indicated and asks which drug.

The framework: first-line classes plus compelling indications

The 2025 AHA/ACC guideline kept the 2017 first-line classes. Beta blockers, alpha blockers, central agents, direct vasodilators and mineralocorticoid receptor antagonists are reserved for specific indications or resistant hypertension. Stage 2 hypertension starts with two first-line agents from different classes, preferably in one pill, whatever the comorbidity, so most comorbidity questions are really asking which class must be in the regimen.

A practical sequence for any vignette:

1. Is there a compelling indication (CKD or albuminuria, HFrEF, prior myocardial infarction or angina, prior stroke)? If so, that class comes first.
2. Is there a contraindication (pregnancy or planned pregnancy, angioedema history, bilateral renal artery stenosis, hyperkalemia, gout)? Remove those classes.
3. Is the pressure in stage 2? Pair the required class with a second first-line agent.

Drug choice by comorbidity

Diabetes

Diabetes makes any stage 1 pressure a treatment threshold, because diabetes is one of the stand-alone triggers for medication in the 2025 guideline. The goal is under 130/80.

The drug choice depends on the urine albumin-to-creatinine ratio, which the 2025 guideline now orders for every adult with hypertension. With albuminuria (30 mg/g or higher) or reduced eGFR, an ACE inhibitor or ARB is the class that slows kidney progression, and it belongs in the regimen. Without albuminuria, a thiazide-type diuretic, calcium channel blocker or RAS blocker is equally acceptable. Thiazides can raise glucose modestly; this is not a reason to avoid them, only to monitor.

Kidney and cardiovascular protection in type 2 diabetes also comes from glucose-lowering drugs with proven benefit (SGLT2 inhibitors, GLP-1 receptor agonists) under the diabetes and kidney guidelines, but those are not substitutes for the antihypertensive.

Chronic kidney disease

The 2025 guideline defines CKD for this purpose as eGFR under 60 mL/min/1.73 m2 or albuminuria of 30 mg/g or more, and recommends an ACE inhibitor or an ARB, but not both (class 1). Its benefit is greatest with albuminuria; without albuminuria the RAS blocker is still reasonable for cardiovascular protection, but it is less decisive.

Practical points the exam uses:

• Check potassium and creatinine within 1 to 2 weeks of starting or increasing the dose. A modest creatinine rise reflects reduced intraglomerular pressure and is expected; a large rise suggests volume depletion or renal artery stenosis (confirm the tolerated percentage in the current guideline).
• Potassium-enriched salt substitutes, recommended for many adults, are avoided in CKD and with potassium-retaining drugs.
• As eGFR falls, thiazides lose potency and a loop diuretic often becomes the diuretic of choice for volume control.
• Refer to nephrology for eGFR under 30, rapid decline, heavy albuminuria or difficult hyperkalemia.

Heart failure

Reduced ejection fraction

For HFrEF, the antihypertensive regimen is the heart failure regimen. The 2022 AHA/ACC/HFSA guideline gives class 1 recommendations to four drug classes: an ARNI (sacubitril-valsartan) or, when an ARNI is not feasible, an ACE inhibitor or ARB; one of the three proven beta blockers (bisoprolol, carvedilol, metoprolol succinate); an MRA when eGFR is above 30 and potassium below 5.0 mEq/L; and an SGLT2 inhibitor. Titrating these to target doses usually controls the pressure.

Nondihydropyridine calcium channel blockers (diltiazem, verapamil) are class 3: harm in HFrEF because of negative inotropy. If pressure stays high on full GDMT, amlodipine is an acceptable add-on; it is neutral for heart failure outcomes. NSAIDs and thiazolidinediones worsen heart failure and should be stopped.

Preserved ejection fraction

For HFpEF, the 2022 guideline gives a class 1 recommendation to titrating medication to the blood pressure goal, a class 2a recommendation to an SGLT2 inhibitor, and class 2b to an MRA, ARB or ARNI, particularly at the lower end of the ejection fraction range. Diuretics treat congestion. An ACC expert consensus pathway on HFpEF updated in 2026 adds newer options, including a nonsteroidal MRA and incretin-based therapy for patients with obesity; confirm details in the current document.

Coronary disease and stroke

After myocardial infarction or with stable angina, a beta blocker and an ACE inhibitor or ARB are the anchor drugs in the 2017 guideline, with a dihydropyridine calcium channel blocker, thiazide or MRA added as needed. Long-acting dihydropyridines also treat angina; short-acting nifedipine is avoided.

For secondary stroke prevention, a thiazide-type diuretic, an ACE inhibitor or ARB, or the combination is preferred, with a long-term goal of under 130/80. Acute stroke management belongs to the emergency setting: the 2025 guideline warns that driving systolic pressure below 140 in the first 24 to 72 hours after successful thrombectomy worsens outcomes.

Pregnancy and women of reproductive potential

Chronic hypertension in pregnancy is treated at 140/90 mm Hg or higher with a goal under 140/90. Labetalol and extended-release nifedipine are the preferred first-line oral agents, with hydralazine used in some settings. ACE inhibitors, ARBs and direct renin inhibitors are contraindicated because of fetal kidney injury, oligohydramnios and skeletal malformations.

For a woman of reproductive age, the safest prescribing plan is made before pregnancy: if an ACE inhibitor or ARB is chosen for a compelling indication, pair it with reliable contraception counseling and a plan to switch before conception. In pregnancy, chronic hypertension is a high-risk factor for preeclampsia, and the USPSTF recommends low-dose aspirin (81 mg daily) after 12 weeks of gestation for high-risk patients. During lactation, labetalol, nifedipine and the ACE inhibitors enalapril and captopril are generally considered compatible.

Older adults

The goal of under 130/80 applies to community-dwelling adults 65 and older who can take medication, and lower systolic pressure also protects against cognitive decline. Frailty, limited life expectancy, residence in long-term care and orthostatic hypotension move the target to shared decision-making.

Alpha blockers are not first-line antihypertensives even in men with benign prostatic hyperplasia; they may be added for urinary symptoms when the pressure allows.

Monitoring and follow-up

Reassess about 1 month after starting or changing therapy and monthly until the goal is reached, then every 3 to 6 months. Laboratory checks follow the drug: potassium and creatinine after an ACE inhibitor, ARB or MRA; sodium, potassium, glucose and uric acid after a thiazide. Home readings guide titration. Refer for resistant hypertension, suspected secondary hypertension, CKD with eGFR under 30, and hypertension in pregnancy without obstetric co-management.

Patient education

• ACE inhibitors: report lip, tongue or face swelling at once (angioedema) and a persistent dry cough.
• RAS blockers and MRAs: avoid potassium supplements and potassium salt substitutes unless prescribed; hold during vomiting, diarrhea or poor intake if the provider has given sick-day instructions.
• Thiazides: take in the morning, report muscle cramps or gout flares.
• Calcium channel blockers: ankle swelling is common and dose-related.
• Women of reproductive age on RAS blockers: use contraception and call before trying to conceive.
• Everyone: rise slowly, bring the home log, avoid NSAIDs and decongestants.

How the exam tests this

• The albuminuria trap. A patient with diabetes and an albumin-to-creatinine ratio of 300 mg/g offered amlodipine alone: wrong, because the regimen needs an ACE inhibitor or ARB.
• The dual-blockade trap. Lisinopril plus losartan "for extra kidney protection" is always wrong.
• The HFrEF trap. Diltiazem for blood pressure or rate in a patient with an ejection fraction of 30 percent is harmful.
• The pregnancy trap. A woman on lisinopril who reports a positive pregnancy test needs the drug stopped and switched to labetalol or extended-release nifedipine, not a dose reduction.
• The beta blocker trap. Atenolol or metoprolol for uncomplicated hypertension is a distractor; after myocardial infarction it is correct.
• The gout trap. A thiazide in a patient with recurrent gout is the wrong first choice.

Practice question

A 61-year-old man with type 2 diabetes returns to review home readings. His 7-day home average is 146/88 mm Hg, matching two office averages of 148/90 and 144/88 mm Hg. A1c is 7.4 percent on metformin. eGFR is 54 mL/min/1.73 m2, potassium is 4.6 mEq/L and urine albumin-to-creatinine ratio is 310 mg/g on two samples. He has no history of heart failure or coronary disease. Which of the following is the most appropriate antihypertensive regimen?

• A. Amlodipine 5 mg daily
• B. Lisinopril and losartan
• C. A single-pill combination of an ARB and amlodipine
• D. Metoprolol succinate and hydrochlorothiazide

Answer: C. He has stage 2 hypertension with diabetes, CKD and severely increased albuminuria, so the regimen needs a RAS blocker and a second first-line class, ideally in one pill. Option A omits the ACE inhibitor or ARB that albuminuria requires and is a single agent for stage 2. Option B combines an ACE inhibitor and an ARB, which raises hyperkalemia and kidney injury risk without benefit. Option D uses a beta blocker without a compelling indication and leaves out the RAS blocker.

Key points

Related NPPace guides

• Heart Failure Follow-Up in Primary Care: GDMT, Weights, Labs and When to Refer
• Hypertension on the NP Exam: Staging, When to Start Medication and the First Drug
• Statin Decisions by ASCVD Risk: Who Gets a Statin, Which Intensity and How to Monitor
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?